A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Gastric Neoplasm|Solid Tumors
Interventions: DRUG: ARX788
Sponsor: Ambrx, Inc.